These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

103 related articles for article (PubMed ID: 38031882)

  • 1. Treatment patterns of systemic drug use in Japanese patients with plaque psoriasis: A retrospective chart review.
    Tada Y; Komine M; Okubo Y; Habiro K; Tsuritani K; Morita A
    J Dermatol; 2024 Feb; 51(2):210-222. PubMed ID: 38031882
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long-term Persistence of First-line Biologics for Patients With Psoriasis and Psoriatic Arthritis in the French Health Insurance Database.
    Pina Vegas L; Penso L; Claudepierre P; Sbidian E
    JAMA Dermatol; 2022 May; 158(5):513-522. PubMed ID: 35319735
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment patterns, healthcare resource utilization, and costs in patients with moderate-to-severe psoriasis treated with systemic therapy in Japan: A retrospective claims database study.
    Tada Y; Kim H; Spanopoulos D; Habiro K; Tsuritani K; Yamada Y; Mandal A; Zhong Y; Hikichi Y
    J Dermatol; 2022 Nov; 49(11):1106-1117. PubMed ID: 35946343
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment Patterns for Targeted Therapies, Non-Targeted Therapies, and Drug Holidays in Patients with Psoriasis.
    Armstrong A; Xia Q; John AR; Patel V; Seigel L
    Dermatol Ther (Heidelb); 2022 Sep; 12(9):2087-2103. PubMed ID: 35947341
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Drug survival of IL-12/23, IL-17 and IL-23 inhibitors for moderate-to-severe plaque psoriasis: a retrospective multicenter real-world experience on 5932 treatment courses - IL PSO (Italian landscape psoriasis).
    Gargiulo L; Ibba L; Malagoli P; Balato A; Bardazzi F; Burlando M; Carrera CG; Damiani G; Dapavo P; Dini V; Gaiani FM; Girolomoni G; Guarneri C; Lasagni C; Loconsole F; Marzano AV; Megna M; Mercuri SR; Travaglini M; Costanzo A; Narcisi A
    Front Immunol; 2023; 14():1341708. PubMed ID: 38274801
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A multinational, prospective, observational study to estimate complete skin clearance in patients with moderate-to-severe plaque PSOriasis treated with BIOlogics in a REAL world setting (PSO-BIO-REAL).
    Seneschal J; Lacour JP; Bewley A; Faurby M; Paul C; Pellacani G; De Simone C; Horne L; Sohrt A; Augustin M; Hammond E; Reich K
    J Eur Acad Dermatol Venereol; 2020 Nov; 34(11):2566-2573. PubMed ID: 32364296
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Persistence of second-line biologics in psoriasis after first-line biologic failure: a nationwide cohort study from the French health insurance database (SNDS).
    Marcombes C; Penso L; Weill A; Dray-Spira R; Zureik M; Sbidian E
    Br J Dermatol; 2023 Oct; 189(5):561-568. PubMed ID: 37479503
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment persistence of interleukin-17 inhibitor class drugs among patients with psoriasis in Japan: a retrospective database study.
    Wang C; Torisu-Itakura H; Hanada T; Matsuo T; Cai Z; Osaga S; Aranishi T
    J Dermatolog Treat; 2023 Dec; 34(1):2229465. PubMed ID: 37403477
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Real-world, long-term treatment patterns of commonly used biologics in Canadian patients with moderate-to-severe chronic plaque psoriasis.
    Gooderham MJ; Lynde C; Turchin I; Avadisian M; Labelle M; Papp KA
    J Dermatol; 2022 Jan; 49(1):95-105. PubMed ID: 34747071
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Survival rates of systemic interventions for psoriasis in the Western Japan Psoriasis Registry: A multicenter retrospective study.
    Yanase T; Tsuruta N; Yamaguchi K; Ohata C; Ohyama B; Katayama E; Sugita K; Kuwashiro M; Hashimoto A; Yonekura K; Higashi Y; Murota H; Koike Y; Matsuzaka Y; Kikuchi S; Hatano Y; Saito K; Takahashi K; Miyagi T; Kaneko S; Ota M; Harada K; Morizane S; Ikeda K; Furue M; Nakahara T; Okazaki F; Sasaki N; Okada E; Yoshida Y; Ito K; Imafuku S
    J Dermatol; 2023 Jun; 50(6):753-765. PubMed ID: 36786158
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Analysis of Drug Utilization in Patients with Psoriasis: A Real-World Retrospective Study Among the Italian Population.
    Perrone V; Losi S; Sabatino S; Mezzetti M; Dovizio M; Sangiorgi D; Degli Esposti L
    Psoriasis (Auckl); 2023; 13():1-9. PubMed ID: 36891082
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparative Effectiveness of Biologics Across Subgroups of Patients with Moderate-to-Severe Plaque Psoriasis: Results at Week 12 from the PSoHO Study in a Real-World Setting.
    Lynde C; Riedl E; Maul JT; Torres T; Pinter A; Fabbrocini G; Daniele F; Brnabic A; Reed C; Wilhelm S; Holzkämper T; Schuster C; Puig L
    Adv Ther; 2023 Mar; 40(3):869-886. PubMed ID: 36515803
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Real-world treatment patterns and healthcare costs among biologic-naive patients initiating apremilast or biologics for the treatment of psoriasis.
    Wu JJ; Pelletier C; Ung B; Tian M
    J Med Econ; 2019 Apr; 22(4):365-371. PubMed ID: 30652520
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of the Safety and Efficacy of Tumor Necrosis Factor Inhibitors and Interleukin-17 Inhibitors in Patients With Psoriasis.
    Green LJ; Yamauchi PS; Kircik LH
    J Drugs Dermatol; 2019 Aug; 18(8):776-788. PubMed ID: 31424708
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Persistence, effectiveness, and real-world outcomes in psoriasis patients treated with secukinumab in Portugal.
    Mendes-Bastos P; Morais P; Ferreira P; Loureiro M; Sanganha J; Santiago L; Basto AS; Henrique M
    Dermatol Ther; 2022 Jul; 35(7):e15510. PubMed ID: 35419886
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of Health Care Costs Among Patients with Psoriasis Initiating Ixekizumab, Secukinumab, or Adalimumab.
    Blauvelt A; Shi N; Zhu B; Burge R; Malatestinic WN; Lin CY; Lew CR; Zimmerman NM; Goldblum OM; Murage MJ
    J Manag Care Spec Pharm; 2019 Dec; 25(12):1366-1376. PubMed ID: 31778621
    [TBL] [Abstract][Full Text] [Related]  

  • 17. PAPA Syndrome: Challenges in Achieving Long-Term Remission.
    Smajlović H; Prohić A
    Acta Dermatovenerol Croat; 2023 Nov; 31(2):106-109. PubMed ID: 38006373
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treating the skin with biologics in patients with psoriasis decreases the incidence of psoriatic arthritis.
    Acosta Felquer ML; LoGiudice L; Galimberti ML; Rosa J; Mazzuoccolo L; Soriano ER
    Ann Rheum Dis; 2022 Jan; 81(1):74-79. PubMed ID: 34281904
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparative risk of serious infections among real-world users of biologics for psoriasis or psoriatic arthritis.
    Li X; Andersen KM; Chang HY; Curtis JR; Alexander GC
    Ann Rheum Dis; 2020 Feb; 79(2):285-291. PubMed ID: 31672774
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Real-world retention rates and effectiveness of secukinumab in psoriasis: Results from a multicenter cohort study (RAILWAY).
    Tada Y; Morita A; Yamanaka K; Kono M; Imafuku S; Okubo Y; Yamazaki F; Kawamura T; Itakura A; Ohtsuki M
    J Dermatol; 2023 Nov; 50(11):1415-1426. PubMed ID: 37615243
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.